SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
📊
Treatment Reviews
See user reviews and ratings for SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
🔬
Mega-Study
See real-world data analysis for SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
📚
Meta-Analysis
See a meta-analysis of all available research
🔍
Clinical Trials
See clinical trials related to SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years